Although the clinical data is currently lacking from breast cancer patients, Nrf2 up-regulation and consequent antioxidant enzyme induction and chemoresistance may explain why the patients with the worst prognosis have low 8-oxodG levels at the initial situation. Here, NFE2L2 is linked to breast cancer.